Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4777-4783

  Reece, Donna E ^a   Rodriguez, Giovanni Piza ^a   Chen, Christine ^a   Trudel, Suzanne ^a   Kukreti, Vishal ^a   Mikhael, Joseph ^a   Pantoja, Mariela ^a   Xu, Wei ^a   Stewart, A Keith ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUPHORIA; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PYRAZINES; SURVIVAL ANALYSIS;

EID: 54249122860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2372     Document Type: Article

References (22)

1. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). J Clin Oncol 24:427s, 2006 (suppl; abstr 7521)
2. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
3. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
4. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
5. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al: The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18:856-863, 2004
6. Offidani M, Bringhen S, Corvatta L, et al: Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: A case-matched study in advanced multiple myeloma. Eur J Haematol 78:297-302, 2007
7. Richardson PG, Mitsiades C, Ghobrial I, et al: Beyond single-agent bortezomib: Combination regimens in relapsed multiple myeloma. Curr Opin Oncol 18:598-608, 2006
8. Orlowski RZ, Nagler A, Sonneveld P, et al: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 25:3892-3901, 2007
9. Wilson K, Shelley W, Belch A, et al: Weekly cyclophosphamide and alternate-day prednisone: An effective secondary therapy in multiple myeloma. Cancer Treat Rep 71:981-982, 1987
10. Brandes LJ, Israels LG: Weekly low-dose cyclophosphamide and alternate-day prednisone: An effective low toxicity regimen for advanced myeloma. Eur J Haematol 39:362-368, 1987
11. de Weerdt O, van de Donk NW, Veth G, et al: Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 59:50-56, 2001
12. Trieu Y, Trudel S, Pond GR, et al: Weekly cyclophosphamide and alternate-day prednisone: An effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 80: 1578-1582, 2005
13. Berenson JR, Yang HH, Sadler K, et al: Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937-944, 2006
14. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. Br J Haematol 102:1115-1123, 1998
15. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Lonial S, Waller EK, Richardson PG, et al: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777-3784, 2005
18. Rajkumar SV, Jacobus S, Callander N, et al: Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 25: 447s, 2007 (suppl; abstr LBA8025)
19. Chanan-Khan AA, Sonneveld P, Schuster MW, et al: Analysis of varicella zoster virus reactivation among bortezomib-treated patients in the APEX study. Blood 108:1009a, 2006 (abstr 3535)
20. Chang H, Trieu Y, Qi X, et al: Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 31:779-782, 2007
21. Sagaster V, Ludwig H, Kaufmann H, et al: Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21:164-168, 2007
22. Berenson JR, Jagannath S, Barlogie B, et al: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104:2141-2148, 2005